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Abstract
Background: Low back pain (LBP) is a major health problem in modern society, with 70-85% of the population
experiencing LBP at some time in their lives. Each year, 5-10% of the workforce misses work due to LBP, most for
less than 7 days. Almost 10% of all patients are at risk of developing chronic pain and disability. Little clinical
evidence is available for the majority of treatments used in LBP therapy. However, moderate evidence exists for
interdisciplinary rehabilitation, exercise, acupuncture, spinal manipulation, and cognitive behavioral therapy for
subacute and chronic LBP. The SMATH
® system (system for automatic thermomechanic massage in health) is a
new medical device (MD) that combines basic principles of mechanical massage, thermotherapy, acupressure,
infrared therapy, and moxibustion. SMATH
® is suitable for automatic multidisciplinary treatment on patients with
non-specific sub-acute and chronic LBP.
Methods/design: This paper describes the protocol for a double-blinded, sham-controlled, randomized, single-
center short term clinical trial in patients with non-specific sub-acute and chronic LBP aged 18 to 70 years. The
primary outcome will be the effectiveness of SMATH
® versus sham therapy (medical device without active
principles) determined by evaluating self perceived physical function with Roland Morris Disability Questionnaire
(RMDQ) scores after 4 weeks of treatment (end of treatment). Major secondary outcome will be effectiveness of
SMATH
® determined by evaluating self perceived physical function comparing RMDQ scores between end of
treatment and baseline. The trial part of the study will take 7 months while observational follow-up will take 11
months. The sample size will be 72 participants (36 for each arm). The project has been approved by the Ethical
Committee of Cremona Hospital, Italy on 29 November 2010.
Discussion: Compared to other medical specialties, physical and rehabilitation medicine (PRM) has not yet
received the deserved recognition from clinicians and researchers in the scientific community, especially for
medical devices. The best way to change this disadvantage is through well-conducted clinical research in sham-
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Background
Low back pain (LBP) is a major health problem in mod-
ern society; 70-85% of the population will experience
LBP at some time in their lives [1]. Each year, 5-10% of
the workforce misses work due to LBP, the majority for
less than 7 days [2]. Almost 10% of all patients are at
risk of developing chronic pain and disability, account-
ing for more than 90% of the costs associated with
back-related disability [3]. LBP incurs substantial treat-
ment and productivity costs worldwide [4]. Healthcare
and social costs for LBP are increasing rapidly. In the
United States, healthcare costs among people with LBP
increased 65% between 1997 and 2005, more rapidly
than overall healthcare costs [5]. In the United States,
chronic LBP is estimated to cost Americans over 70 bil-
lion dollars per year in health care expenditures [6]. The
total cost of treatment, lost work days, and disability
due to chronic pain in 1995 and 1996 was estimated to
be between 150 and 215 billion dollars [7]. In the UK,
1.3 million people receive physiotherapy for LBP each
year, with a global cost of £150 million for the National
Health System (NHS) [8]. In Italy, the global economic
impact of LBP is approximately €24 billion per year, and
patients pay almost all fees.
LBP has been difficult to treat solely using medical
interventions due to the complex interplay of biological,
psychological, and social factors in its onset and persis-
tence. LBP is usually a benign and self-limiting condition,
but many patients look for some type of therapy to
relieve their symptoms and provide hope for a cure. For
this reason, more than 50 potential therapies promise to
relieve the pain [2,9], lessen the suffering, and offer a
cure for this problem. However, sound evidence exists
for a small number of these therapies [9]. For the inter-
ventions with multiple reviews, conflicting conclusions
have been reached about effectiveness due to the hetero-
geneity and poor quality of the trials, but there are more
qualitative systematic reviews than meta-analyses, and
two-thirds of systematic review authors emphasize that
more high quality trials are needed [10]. Despite
advances in knowledge, technology, and procedures, no
medical treatment has been demonstrated to consistently
and completely alleviate LBP. Clinical evidence for the
majority of treatments used in LBP therapy is also incon-
sistent. However, moderate evidence exists for interdisci-
plinary rehabilitation, exercise, acupuncture, spinal
manipulation, and cognitive behavioral therapy for sub-
acute and chronic LBP [5,11]. In particular, multidisci-
plinary interventions seem to be the most promising
approach for patients with sub-acute and chronic LBP
[12]. Intensive multidisciplinary biopsychosocial rehabili-
tation with a functional restoration approach has been
s h o w nt or e d u c ep a i na n di m p r o v ef u n c t i o ni np a t i e n t s
with chronic LBP [13]. In addition, empirical evidence
has shown the sort of information and advice that should
be given to patients with back pain, confirming that such
information and advice may be a potent element of the
health care intervention [14]. Soft-tissue massage is
thought to improve physiological and clinical outcomes
by offering symptomatic pain relief through physical and
mental relaxation and increasing the pain threshold via
the release of endorphins [2,15]. The gate-control theory
predicts that massaging a particular area stimulates large
diameter nerve fibers. These fibers have an inhibitory
electrical input to T cells, which are the first cells to pro-
ject into the central nervous system within the spinal
cord [2]. T-cell activity is likely depressed, whereas small
diameter nerve fibers (nociceptive fibers) have an excita-
tory input, and pain relief follows [16]. Massage therapy
may provide benefits by shifting the autonomic nervous
system from a state of sympathetic response to a state of
parasympathetic response. Massage is similar or superior
to other conservative therapies, such as exercises, mobili-
zation, relaxation, physical therapy, acupuncture, and
self-care education [2]. Massage is beneficial for patients
with sub-acute and chronic nonspecific LBP in terms of
improving symptoms and function, but the benefits of
massage increase when combined with exercises and
education [2]. Massage has powerful analgesic effects if
applied to acupuncture points, a technique known as
“acupressure” [2]. Two studies that compared massage to
inert treatment (sham therapies) showed that massage is
superior for pain and function in both short and long-
term follow-up [17,18]. No serious adverse events were
reported by any patient in the studies reviewed [2]. Mas-
sage alone is unlikely to be cost-effective [5]. Focusing on
high-quality randomized controlled trials (RCTs) with a
sufficient sample size to draw firm conclusions is particu-
larly recommended for future research involving LBP
therapies [12].
Trial Rationale
SMATH
® is a new medical device that combines basic
principles of mechanical massage, thermotherapy,
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SMATH
® is included in the “conservative treatments”
category [13]. This device is capable of releasing modu-
lated and controlled thermomechanic energy on the
patient following a programmable and fully reproducible
automatic treatment program selected by the operator.
Energy (thermomechanic and infrared) is released at the
same time under the spine and legs of the patient. We
think this system provides a true automatic multidisci-
plinary treatment for patients with sub-acute and
chronic LBP. The SMATH
® system should theoretically
be capable of combining the single clinical benefits of
massage, thermotherapy, infrared, and acupressure,
removing the dependency on operator capability, though
obviously missing some elements of human touch, and
providing maximum automaticity and reproducibility
and producing a real clinical added value for patients.
The literature involving different reviews show that little
clinical evidence exists on the use of these endorsed
therapies on their own. In particular, there is little evi-
dence for massage performed by hands or a mechanical
device, or and for superficial heat release [12]. No evi-
dence is available for thermotherapy [13], or for moxi-
bustion, infrared therapy, and acupressure. On the other
hand, moderate evidence indicates the effectiveness of
multidisciplinary treatment compared to other kinds of
active treatment in regards to pain intensity at short-
term follow-up [12]. The SMATH
® system was devel-
oped in an attempt to create an effectiveness advantage
by combining different basic theoretical principles. The
first clinical results, from the safety clinical study invol-
ving 46 patients inside the process to obtain the Eur-
opean Conformity (CE) mark for SMATH
®,s h o w e dt h e
following: RMDQ average score of 10.96 (sd = 3.04; p <
0.05) at baseline and 3.21 (sd = 2.99; p < 0.05) after 3
months, and the average quality adjusted life year
(QALY) was 0.46 (sd = 0.13; p < 0.05) at baseline and
0.81 (sd = 0.12; p < 0.05) after 3 months. These data
have not been published because they were not suitable
for publication and represented the results obtained by
one clinical study in which the primary outcome was
the demonstration of clinical safety. The internal clinical
report concerning this study has been delivered to the
notified body in charge of the CE mark process. The
SMATH
® system obtained the CE mark on 20 Decem-
ber 2010. The current RCT was designed to investigate
and test the SMATH
® system for use in LBP therapy.
The cost/effectiveness ratio for the SMATH
® system
may also be interesting and could play an important
role in the Italian NHS strategy for LBP interventions.
An HTA procedure has already been launched in Italy
for this new therapy. Like all new technologies and
interventions, the clinical effectiveness of the SMATH
®
system has to be proven by clinical studies in a PRM
context. Compared to other medical specialties, PRM
has not yet received the recognition deserved from clini-
cians and researchers in the scientific community, espe-
cially for medical devices [19]. We think this
unfavorable scenario is due to several reasons, one of
which is the lack of high-quality clinical trials in the
PRM field. Conducting double-blind placebo-controlled
trials in the specialty is difficult; the majority of studies
in PRM are practically based on clinical observation,
uncontrolled observational studies, or clinical trials com-
paring two different active therapies. Consequently,
these studies are not suitable for providing sufficient
proof of efficacy for these therapeutic modalities. The
only scientifically recognized way to achieve this goal is
to design and manage high-quality double-blind pla-
cebo-controlled trials. Sham treatment groups in clinical
trials are essential for improving the level of evidence-
based practice in PRM. This trial was conceived to
reduce the lack of evidence and quality for LBP therapy.
No major and minor adverse events or adverse effects
have been observed during the use SMATH
® on
patients with LBP. The SMATH
® system has the CE
mark as it has passed all tests concerning safety for the
patient, operators, and environment. For this reason, no
adverse events are expected during this clinical study.
H o w e v e r ,i fa d v e r s ee v e n t so c c u r ,t h e yw i l lb er e p o r t e d
to the regulatory authority and ethics committee in
accordance with applicable regulations. Trial results will
be used to inform HTA procedure already involving
SMATH
® therapy for health care policies regarding the
treatment of LBP in Italy.
Methods
Design
This is a double-blinded, sham-controlled, randomized,
single-center short term clinical trial involving 72 partici-
pants. Thirty-six participants will be treated with
SMATH
® therapy and compared to 36 participants trea-
ted with sham therapy (same medical device without
active principles). All participants are patients with non-
specific sub-acute and chronic LBP, aged 18 to 70 years.
Exclusion criteria verification will be done at baseline (T1)
with the identification of eligible participants. One week
after T1 (T2), eligible participants who have signed
informed consent and satisfy the inclusion criteria will be
randomized into either the SMATH
® or sham groups.
Participants who are not randomized will be submitted to
the most suitable therapy by the investigators and sent to
TF1 to enter in the observational follow-up. Randomized
participants will attend clinic visits at T2 (one week after
T1), T3 (two weeks after T2) and T4 (two weeks after T3).
The design of the clinical trial is depicted in Figure 1. At
T4, treatments will be complete and all participants can
continue the most suitable therapy, as indicated by the
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Page 3 of 12• Population: Patients with nonspecific subacute and chronic low back pain aged > 18 years  and < 70  years, according to the inclusion and 
exclusion criteria established in the protocol. 
• Method: Randomized double-blind controlled trial, randomized versus sham therapy (1) over short term. 
 
 
 
 
 
 
 
T1: anamnesis, clinical assessment, RMDQ compilation to verify eligibility , exclusion criteria verification, delivery informed consent, information module, authorizations  to use patient data, information letter for family 
physician, special educational booklet. 
T2: clinical assessment, inclusion criteria verification, questionnaire compilation (VAS, RMQD, EQ-5D), eligibility, randomization, treatment planning, first treatment. 
T3: clinical assessment, questionnaire compilation (VAS, RMDQ). 
T4: clinical assessment, questionnaire compilation (VAS, RMDQ, EQ-5D), randomized phase conclusion, follow-up enrolment, statistical analysis for short-term primary  and secondary outcomes 
(1)  Fregni et al. Challenges and Recommendations for Placebo Controls in Randomized Trials in Physical and Rehabilitation Medicine. A report of the International Placebo Symposium Working Group. Am J 
Phys Med Rehabil 2010;89:160-172. 
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Group A: SMATH 36 participants 
           Group B: SHAM 36 participants 
  T1    T2 
Run in 1 week 
  T3    T4 
Follow-up 
1st  week  2nd  week  3rd  week  4th  week 
(4 treatments)  (4  treatments)  (3 treatments)  (3 treatments) 
(4 treatments)  (4 treatments)  (3 treatments)  (3 treatments) 
1st  week  2nd  week  3rd  week  4th  week 
Figure 1 Clinical Study Design.
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2investigators, and enter the long-term observational fol-
low-up phase, which will last 11 months. All participants
will be followed starting at TF1 (same time as T4,) for 11
months and will attend clinic visits at 1 month (TF2), 4
months (TF3), 7 months (TF4), and 11 months (TF5) after
TF1. The design of the observational follow-up period is
depicted in Figure 2.
Eligibility
Subjects with sub-acute and chronic non-specific LBP
diagnosed according to generally accepted scientific cri-
teria [13] were enrolled. Inclusion criteria were as fol-
lows: aged between 18 and 70 years, ability to sign
informed consent, ability to complete the study, ability
to complete the questionnaires, RMDQ score ≥ 4a tT 2
[20], and negative answers on all exclusion questions at
T1. The rationale for the inclusion criteria is provided
in Table 1.
Exclusion criteria were as follows: pregnancy (real or
suspected) or breast-feeding; receiving physical therapy
treatments in the 15 days preceding T1; treatment with
cortisone in the month preceding T1, implanted with
pacemaker or implantable cardioverter defibrillators
(ICD) or, more generally, a user of active implantable
devices; use of medullar stimulators and infusion
pumps; recent or ongoing deep venous thrombosis
(DVT); use of spine stabilization devices; serious osteo-
porosis associated with bone fracture risk, including soft
or acutely infected bone tissues; acute cardiovascular
disease; neoplastic disease; systemic rheumatic disease;
or traumatic spinal episodes in the 3 months preceding
T1. The rationale for the exclusion criteria is provided
in Table 2.
Setting and locations where the data will be collected
A special area inside the Head Investigator’s office in
the Hospital will be dedicated to data collection and
storage. Case report forms (CRFs) for the enrolled sub-
jects will be kept strictly inside this area. Treatment
plan sheets on which the treatment plan for each ran-
domized participant will be recorded will be delivered
externally by the technician in charge of executing the
treatment. Before randomization, randomization envel-
opes will be held in this area by the Head Investigator
and remain sealed, even after delivery, until used by
the technician in charge of administering the treat-
ment. Access to the CRFs by the investigators and
monitor will be authorized by the Head Investigator.
The technicians in charge of administering treatment
will be responsible for storing the envelopes and treat-
ment plan after randomization and treatment plan;
they will have to practice maximum confidentiality
about their contents as investigators will not have
access to this information.
Randomization
A simple randomization process has been conceived
through three different steps according to the Consoli-
dated Standards of Reporting Trials (CONSORT) state-
ment: sequence generation, allocation concealment, and
implementation.
Sequence generation has been achieved through a
“congruential multiplier” statistical algorithm applica-
tion, using IBM Statistical Package for Social Sciences
(SPSS) Version 19 [21,22] and was stratified with 1:1
allocation random block size of 36. The randomization
list reports a progressive randomization number for ran-
domized participants (from 1 to 72), and the treatment
(A or B) will be assigned for each of them.
For allocation concealment, the randomization list
was produced in three numbered copies. The first copy
was delivered to the Ethics Committee inside an envel-
ope sealed with warm sealing wax. A second copy was
delivered to the Head Investigator in a similar sealed
envelope. The Head Investigator will save his copy in a
locked box in his office. He can open the envelope in
the case an emergency arises. A third copy has been
kept by the monitor of the study who managed the
sequence generation. The monitor also prepared 72 opa-
que red envelopes containing randomization sheets. On
each envelope is a number (from 1 to 72) and space for
the patient’s name and date of birth. The randomization
sheet (opaque red) reports the progressive randomiza-
tion number and assigned treatment (A or B) based on
the randomization list. All of the envelopes have been
closed and sealed with warm sealing wax. The 72 rando-
mization envelopes were delivered to the Head Investi-
gator, who will keep them in a locked box in his office.
At the time of randomization, the investigator who deci-
des to randomize the participant will take the first of
the envelopes from the box in order of sequence and
write the participant’s name and date of birth on the
envelope (to prevent subversion of the allocation
sequence as suggested by Consort 2010, Item 9). Imme-
diately after, the investigator will deliver the closed
envelope and intervention plan to the technician in
charge of administering the treatment. The technician
will open the envelope to start the intervention, saving
the envelope and randomization sheet in a locked box.
The technicians involved in this phase of the study have
been trained and educated to maintain maximum confi-
dentiality concerning allocation concealment. This
method will provide double-blinded conditions. Clinical
investigators who enroll and evaluate participants will
not know which treatment has been assigned to them.
Implementation of the randomization process will
conform with the study requirements and steps
described above. The process involves participant elig-
ibility analysis, obtaining patient information,
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Page 5 of 12• Population: Patients with nonspecific subacute and chronic low back pain aged > 18 years and < 70  years from the end of treatment and drop-
outs in randomized double-blinded controlled trial versus sham therapy and patients not enrolled in T1.  
• Methods: Follow-up clinical study, open, monocenter at long term 
 
 
 
 
 
 
 
TF1 = T4 RCT                                          
TF2: Recent anamnesis, clinical assessment, questionnaire compilation (VAS, RMDQ, EQ-5D) 
TF3, TF4: anamnesis, clinical assessment, questionnaire compilation (VAS, RMDQ) 
TF5: anamnesis, clinical assessment, questionnaire compilation (VAS, RMDQ, EQ-5D), end follow-up statistical analysis                                                                                                
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 1 month         3 months         3 months        4 months 
T1 
T4 
T1F 
TF2  TF3  TF4  TF5 
Non eligible patients 
1 month 
  Drop out patients RCT 
Figure 2 Follow-up Design.
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2enrollment, treatment assignment, and data analysis to
avoid any kind of bias. The implementation process is
depicted in Figure 3.
Interventions for each group
Participants assigned to the SMATH
® therapy group (A
arm) will have 14 treatment sessions of 45 minutes over
4 weeks starting at T2. The treatment module is asso-
ciated with a dedicated educational booklet for each
patient that provides general and behavioral indications
for preventing LBP. In this clinical study, the educa-
tional booklet will be delivered to all enrolled partici-
pants to help them correct their lifestyle during and
after the intervention period. In this dedicated booklet,
different sections explain to the participants spine anat-
omy, LBP, LBP prevention, advantages of physical activ-
ity, suggestions for positions for walking, sleeping, and
to keep weight under control, and exercises to prevent
LBP.
During the first and second week (from T2 to T3), 4
sessions will be done per week, whereas 3 sessions per
week will be planned for the third and fourth week
(from T3 to T4). The SMATH
® system will be set-up
with treatment variables (warm-up time, automatic
treatment program, active element temperature, infrared
insertion) conforming to the scheduled treatment data
sheet delivered to the technician after randomization.
Sham therapy will be implemented using a dedicated
SMATH
® device. This medical device, which was con-
ceived and manufactured exclusively for this clinical
study, has the same external look and design of the
SMATH
® device. The active principles (thermomecha-
nic and infrared energy release) have been fully blocked
in the sham device, but the participants’ perceptions will
be more or less the same (warm, vibration, noise). The
engineering department has made important efforts to
create a device with the appearance of the active
machine, inducing feelings similar to those of the real
Table 2 Rationale for exclusion criteria
Exclusion criteria Rationale
Pregnancy (real or suspected) and breast-feeding These patients have a risk of some alteration due to the mechanical and
thermal energy release
Subjects who received physical therapy treatments in the 15 days
preceding T1
These treatments could influence the results of the study
Subjects treated with cortisone in the month preceding T1 This treatment could influence the results of the study
Subjects implanted with pacemakers and ICDs (implantable
cardioverter defibrillators); more generally, users of active implantable
devices
In order to prevent possible electromagnetic interference between SMATH
®
and the implantable device, which is potentially dangerous for the patient
(cautelative criteria)
Subjects with medullar stimulators and infusion pumps with recent or
ongoing DVT (deep venous thrombosis)
To prevent possible electromagnetic and mechanical interference between
SMATH
® and the implantable device, which is potentially dangerous for the
patient (cautelative criteria)
Subjects with spine stabilization devices These treatments could influence the results of the study
Subjects with serious osteoporosis associated with bone fracture risk Mechanical energy release on these patients could increase bone fracture
risk
Subjects with logically soft or acute infection of bone tissues Thermal and mechanical energy release could increase infection diffusion
Subjects with acute cardiovascular disease These patients need to be submitted to specific clinical evaluation before
being treated for LBP
Subjects with neoplastic disease These patients need to be submitted to specific clinical evaluation before
being treated for LBP
Subjects with systemic rheumatic disease These patients need to be submitted to specific clinical evaluation before
being treated for LBP.
Subjects with traumatic spinal episodes the 3 months preceding T1 Mechanical energy release on these patients could be dangerous.
Table 1 Rationale for Inclusion Criteria
Inclusion criteria Rationale
Age between 18 and 70 years This age interval was chosen in accordance with actual main reviews in PRM [2,10,12]
Ability to sign informed consent Mandatory for participant inclusion in clinical studies (Helsinki Declaration article 22)
Ability to complete the study To prevent drop-outs
Ability to complete the questionnaire Mandatory for accurate data collection
RMDQ score ≥ 4 at T2 From the literature [20]
Negative answers for all exclusion criteria This check performed at T2 confirms that the exclusion evaluation was performed at T1.
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Page 7 of 12device [19]. This effect has been obtained by applying
some technical solutions without releasing any active
energy. Thermal perception is generated using special
lamps with different wavelengths than the real
SMATH
® device with 90% less thermal power (just to
induce the feeling of heat). Infrared emission has been
removed, as well as the active rollers that release
mechanical energy to the back and legs, replaced by an
T1 : anamnesis, clinical assessment, RMDQ compilation to 
verify eligibility , exclusion criteria verification, delivery  of 
informed consent, information module, authorization to use 
patient data, information letter for family physician, special 
educational booklet. 
NO 
Go to TF1 
YES 
Enroll number assignment  
T2 : clinical assessment, inclusion criteria verification, 
questionnaire compilation (VAS, RMQD, EQ-5D), eligibility, 
randomization, treatment planning, first treatment 
NO 
YES 
Randomization : Treatment planning, 
go to the first treatment 
Group B  Group A 
Treatments  Treatments 
T4-TF1 : clinical assessment, questionnaire compilation  
(VAS, RMDQ, EQ-5D), randomized phase conclusion, follow-
up enrollment, statistical analysis for short  term primary  and 
secondary outcomes 
NO 
YES 
Go to the follow-up 
STOP 
Is patient          
eligible ? 
Is  patient 
randomizable? 
Is patient included in follow-
up?
Figure 3 Randomization Implementation Process.
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Page 8 of 12inert, flat wood plate. The sham device will be set-up
with the same treatment variables as the SMATH
®
device. The noise and vibration generated by the sham
device will be the same as that of the SMATH
® system
because the devices have the same mechanical config-
uration, including the same motor and transmission
equipment, operating in the same mode. Despite this
similarity, a therapeutic placebo effect could be intro-
duced by the sham device. This risk has been considered
and accepted as a natural risk of the RCT with a sham
control.
Participants assigned to the sham therapy arm will receive
the same treatment module scheduled for the active
SMATH
® arm (14 sessions in four weeks from T2 to T4).
The participants in the sham arm will also receive the edu-
cational booklet. The SMATH
® and sham devices are
located inside two different therapy boxes and treatment
will be given at separate times to prevent contact between
participants in the different treatment arms. The operators
managing treatments will be the same for the SMATH
®
and sham devices, and they have been trained to answer the
participants’ questions about the procedures. The same
operators will also be trained and educated in keeping parti-
cipants in the study, avoiding an increased drop-out rate.
The main features of the SMATH
® system and sham ver-
sion are presented in Figures 4 and 5, respectively.
Discussion
Outcomes
This clinical study was designed to include the following
general outcome measures: pain, overall improvement,
back-specific functional status, well being (quality of life),
and disability. The questionnaires that will be used to col-
lect data from the participants are: visual analog scale
(VAS) for pain [12], Roland Morris Disability Questionnaire
(RMDQ) for effectiveness, specifically back-specific
disability [12], and Euro Qol-5D questionnaire (EQ-5D) for
quality of life, which is one of the most used and suitable
questionnaires for QALY calculation [5]. These question-
naires were chosen by considering the major systematic
reviews regarding physical and rehabilitory interventions for
sub-acute and chronic non-specific LBP [2,4,9,10,12,15].
Participants will complete the VAS at T2, T3, T4, TF1,
TF2, TF3, TF4, and TF5; RMDQ at T1, T2, T3, T4, TF1,
TF2, TF3, TF4, and TF5; and EQ-5D at T2, T4, TF1, TF2,
and TF5.
Primary outcome
The primary outcome of the trial is represented by the
clinical effectiveness of the SMATH
® system versus
sham therapy after 4 weeks of treatment in patients
with sub-acute and chronic non-specific LBP, deter-
mined by evaluating self perceived physical function
with RMDQ scores. The status of physical function in
participants treated with SMATH
® interventions will be
compared with the status achieved in participants in the
sham control arm at the end of treatment (T4) [12].
Secondary outcomes
The secondary outcomes of the trial are: 1) Effectiveness
of SMATH
® determined by evaluating self perceived
physical function comparing RMDQ scores between end
of treatment and baseline. 2) Pain perception change
from baseline (T2) to end-treatment (T4), evaluated by
VAS scores. 3) Quality of life at different steps of the
study (T2 and T4), evaluated by EQ-5D scores (QALY).
4) Verified general feasibility of the medical device com-
pared to sham therapy in terms of methodology, sample
size, and drop-out rate, among other measures, to con-
stitute a real pilot study and act as a possible reference
 
Main features: 
1.  Four automatic treatment programs for 
mechanical massage. 
2.  Programmable thermal energy release 
between 40°C and  70°C. 
3.  Infrared energy release at 50°C. 
4.  Tilting position capability. 
5.  Mechanical energy and heat release at 
the same time on the back region and 
legs. 
6.  Standard duration of 45 minutes for 
automatic treatments. 
7.  MP3 music player for patient 
relaxation. 
8.  Manual control for active elements. 
9.  Vacuum fluorescent display (VFD) 
control display. 
Figure 4 The SMATH
® System.
  Sham features: 
1.  Four automatic treatment programs 
for mechanical massage. 
2.  Simulated programmable thermal 
energy release between 40°C and  
70°C with effective thermal release 
of 10% set-up value. 
3.  Simulation of infrared energy 
release at 50°C (without energy 
release). 
4.  Tilting position capability. 
5.  Mechanical energy and heat release 
simulation at the same time on the 
back region and legs. 
6.  Standard duration of 45 minutes for 
automatic treatments. 
7.  MP3 music player for patient 
relaxation. 
8.  Manual control for active elements. 
9.  Vacuum fluorescent display (VFD) 
control display. 
Figure 5 The SMATH
® sham version.
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Page 9 of 12for future generations of RCTs involving the medical
device, conforming to the evidence-based medicine
(EBM) criteria for LBP therapy [13] according to the
CONSORT statement based on new methodological evi-
dence and to the International Placebo Symposium
Working Group recommendations [19].
Observational follow-up and duration of the study
Observational follow-up will start at TF1 (T4) and cover
11 months. During this period, all of the participants
will come to the treatment centre to attend clinic visits
one month after TF1 (TF2), 3 months after TF2 (TF3),
3m o n t h sa f t e rT F 3( T F 4 ) ,a n d4m o n t h sa f t e rT F 4
(TF5). Figure 2 shows the design of the observational
follow-up period. The estimated study duration for
enrollment, execution and observational follow-up will
be 18 months.
Assessment of outcomes
Four steps of participant examination are planned in
this RCT (T1, T2, T3, and T4); during which, general
clinical data will be collected about the persistence of
LBP symptoms, previous treatment, morphological data,
patient activity, blood chemistry tests, anamnesis, and
eventual clinically important imaging investigations that
were recently done. The effectiveness of SMATH
® ver-
sus sham will be determined by evaluating self-perceived
physical function with RMDQ scores at T4. The second-
ary outcome of SMATH
® therapy effectiveness will be
determined by evaluating improvements in patients’
motion functionality between T2 and T4 using RMDQ
scores. The evolution of pain perception during the
s t u d yw i l lb em e a s u r e db yV A Ss c o r e ss u b m i t t e db yt h e
participants at T2, T3, and T4. Quality of life for partici-
pants will be estimated by the comparing the EQ-5D
questionnaires submitted at the beginning and end of
treatment (T2 and T4). During the observational follow-
up period all participants will be examined at TF1, TF2,
TF3, TF4, and TF5 for general patient status: anamnesis,
blood pressure, heart rate in beats per minute, and mor-
phological variables (height, weight, Body Mass Index
[BMI]). The RMDQ and VAS questionnaires will be
given on the participants at TF1, TF2, TF3, TF4, and
TF5, and EQ-5D will be given at TF1, TF2, and TF5. All
of the data collected during the study and follow-up will
be reported to the CRF.
Sample size calculation
Due to the difficulty of finding solid references in the
literature regarding the probability of success for differ-
ent arms of RCTs comparing therapy with medical
devices versus sham therapy [19], some basic statistical
assumptions have been made in regards to the level of
inhibition technically introduced into the SMATH
®
active principles to obtain a sham device. The therapeu-
tic effect induced by the sham device has been estimated
to be 10% of the effect induced by the SMATH
® system.
Consequently, the probability of SMATH
® therapy suc-
cess has been fixed at 50% (P1) [2], whereas a probability
of 10% (P2) has been fixed for success with sham ther-
apy. Thus, the success difference between the two study
arms (P1 -P 2) is 40%. This important delta has been
fixed to be statistically significant also in the case of
unexpected placebo effect of sham. The false-positive
risk factor a (type I error rate) has been fixed at 0.05
(5%). The probability of discovering a difference
between the two study arms has been fixed at 90%
(study’sp o w e r ) .B a s e do nt h es t u d y ’sp o w e r ,( 1-b)=
0.9, the false-negative risk factor rate b is 0.1 (10%). The
value of the function f (a, b) was calculated by Geigy’s
tables [23]. Thus, the sample size in each arm of the
study (n) should be n = 26. Drop-out has been consid-
ered to prevent having an insufficient sample at the end
of the study due at the high risk of drop-out of partici-
pants in sham arm. A drop-out rate of 15% (0.15) has
been estimated based on the literature concerning RCT
versus sham in PRM [19]. The sample adjusting factor μ
was calculated using the formula μ =1 / ( 1-R )
2 [24-26],
where R represents the drop-out rate. Therefore, μ =1 /
(1 - 0.15)
2 = 1.3841, and the sample size after correcting
for drop-out will be:n# = nμ = 36. The sample of each
group will be 36 participants for a total study group of
72 subjects.
Statistics and quality
The accuracy and completeness of the collected and
registered data will be checked daily by clinical investi-
gators to provide a suitable level of quality for the study.
The external monitor will be responsible for arranging
random periodic tests of quality throughout the study.
In particular, controls will involve the quality and com-
pleteness of the CRFs, the treatment execution modal-
ities, the drop-out rate, and correct respect of
enrollment criteria application. Data analysis will be
conducted using IBMSPSS 19 [21,22]. The morphologi-
cal and clinical status of participants will be analyzed
statistically. Motion functionality, level of pain percep-
tion, and quality of life will be evaluated through statisti-
cal analysis of the questionnaire scores. Short-term
results will be evaluated to elaborate VAS and RMDQ
scores, and medium and long-term results will be evalu-
ated by EQ-5D scores, which will also be used to calcu-
late the QALY and incremental cost effectiveness ratio
(ICER) index [5,22], which is the most used and suitable
index for analyzing the cost/effectiveness of PRM thera-
pies [5]. Pain perception measured by VAS in the differ-
ent phases and its severity analysis will be evaluated by
analysis of variance using SPSS 19. Event incidence
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® versus sham) will be estimated using Kaplan-
Meier curves, which will be compared using the log-
rank test. Multivariable analysis will be performed using
the Cox model.
Patient information material
Correct involvement and informed participant processes
are key issues for the success and credibility of the
study. Clinical investigators will be responsible for
informing participants and involving them in the most
appropriate way. This goal will be pursued by discussing
the study objectives, risks, benefits, and modalities with
participants at T1. Each participant will make a decision
as to whether they will participate in the study, which
will have to be clearly checked by investigators and
documented. In this study, clinical investigators will sub-
mit and explain to each participant the following docu-
ments: (1) signed informed consent, (2) information
module, (3) authorization to use personal sensitive data
based on privacy law, (4) information letter that will be
delivered to the family physician, (5) the dedicated edu-
cational booklet. This booklet must be considered a part
of the SMATH
® treatment module.
Adverse events
Adverse events will be managed to conform with good
clinical practice and actual normative rules, listed in
additional file 1. All adverse events will be reported to
the regulatory authority and ethics committee in accor-
dance with applicable regulations. The report will spe-
cify the types of events, and whether they were device
related or non-device related, that shall be reported and
the timing for such reporting.
Protocol changes
Eventual unplanned and important changes to the study
protocol involving, for instance, eligibility criteria, inter-
ventions, examination data collection, method of analy-
sis, and outcomes, will be submitted to the ethics
committee as amendments for approval. In the case of
approval and application, they will be reported at the
end of the study. All deviations from the protocol dur-
ing its execution will have to be justified and documen-
ted in CRFs for the participants.
Additional material
Additional file 1: List of the Italian and international laws and
norms for clinical studies. This additional file contains a list of the
italian and international laws and norms which have been respected for
this randomized double-blinded controlled trial. This clinical study has
been designed and will be managed to conform with the following
Italian and international laws and norms listed in additional file 1.
List of abbreviations used
In this manuscript, the following abbreviations have been used:
BMI: Body Mass Index; CRF: Case report form; CE: Conformité Européenne
(European Conformity); CONSORT: Consolidated Standards of Reporting
Trials; DVT: Deep venous thrombosis; EBM: Evidence-based medicine; EQ-5D:
Euro Qol 5D questionnaire; HTA: Health technology assessment; ICD:
Implantable cardioverter defibrillator; ICER: Incremental Cost Effectiveness
Ratio; LBP: Low back pain; MD: Medical device; NHS: National Health System;
PRM: Physical and rehabilitation medicine; QALY: Quality adjusted life year;
RCT: Randomized controlled trial; RMDQ: Roland Morris Disability
Questionnaire; SMATH
®®: System for automatic thermomechanic massage in
health; VAS: Visual analog scale.
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